| Safety assessment of sorafenib in Chinese patients with unresectable hepatocellular carcinoma: subgroup analysis of the GIDEON study | |
| Ye, Sheng-Long; Yang, Jiamei; Bie, Ping; Zhang, Shuijun; Chen, Xiaoping; Liu, Fengyong; Liu, Luming; Zhou, Jie; Dou, Kefeng; Hao, Chunyi | |
| 刊名 | BMC CANCER
 |
| 2018 | |
| 卷号 | 18 |
| ISSN号 | 1471-2407 |
| URL标识 | 查看原文 |
| 语种 | 英语 |
| 内容类型 | 期刊论文 |
| URI标识 | http://www.corc.org.cn/handle/1471x/3600979 |
| 专题 | 复旦大学上海医学院 |
| 推荐引用方式 GB/T 7714 | Ye, Sheng-Long,Yang, Jiamei,Bie, Ping,et al. Safety assessment of sorafenib in Chinese patients with unresectable hepatocellular carcinoma: subgroup analysis of the GIDEON study[J]. BMC CANCER,2018,18. |
| APA | Ye, Sheng-Long.,Yang, Jiamei.,Bie, Ping.,Zhang, Shuijun.,Chen, Xiaoping.,...&Lv, Zhengguang.(2018).Safety assessment of sorafenib in Chinese patients with unresectable hepatocellular carcinoma: subgroup analysis of the GIDEON study.BMC CANCER,18. |
| MLA | Ye, Sheng-Long,et al."Safety assessment of sorafenib in Chinese patients with unresectable hepatocellular carcinoma: subgroup analysis of the GIDEON study".BMC CANCER 18(2018). |
| 个性服务 |
| 查看访问统计 |
| 相关权益政策 |
| 暂无数据 |
| 收藏/分享 |
除非特别说明，本系统中所有内容都受版权保护，并保留所有权利。
修改评论